120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
SGLT2抑制剂在肾脏保护中的作用：基于心血管-肾脏-代谢相互关联的叙述性综述
Received 13 May 2025
Accepted for publication 20 December 2025
Published 20 January 2026 Volume 2026:20 540082
DOI https://doi.org/10.2147/DDDT.S540082
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Anastasios Lymperopoulos
Nan Ye, Hong Cheng
Department of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China
Correspondence: Hong Cheng, Department of Nephrology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, People’s Republic of China, Email drchengh@163.com
Abstract: Cardiovascular-kidney-metabolic (CKM) diseases pose a significant global health burden and are becoming a major healthcare challenge. The intricate interplay among type 2 diabetes mellitus (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD) has been well established. Therefore, comprehensive management and early intervention are crucial to improving patient outcomes and reducing the strain on medical resources. This narrative review discusses the critical role of renal protection in the context of CKM syndrome, with a focus on the importance of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. These drugs play a significant role in renal protection and in managing a variety of metabolic and cardiovascular disorders or risk factors. Additionally, the review underscores the challenges faced in managing CKM syndrome and suggests potential future directions in China. This reflects a comprehensive approach aimed at enhancing public health strategies in managing the complex interplay among kidney health, cardiovascular function, and metabolic status.
Keywords: sodium-glucose cotransporter-2, cardiovascular-kidney-metabolic syndrome, chronic kidney disease, heart failure, cardiovascular disease, type 2 diabetes mellitus
Department of Nephrology, Beijing Anzhen Hospital, Capital Medical University, Beijing, People’s Republic of China
Correspondence: Hong Cheng, Department of Nephrology, Beijing Anzhen Hospital, Capital Medical University, No. 2, Anzhen Road, Chaoyang District, Beijing, 100029, People’s Republic of China, Email drchengh@163.com
Abstract: Cardiovascular-kidney-metabolic (CKM) diseases pose a significant global health burden and are becoming a major healthcare challenge. The intricate interplay among type 2 diabetes mellitus (T2D), cardiovascular disease (CVD) and chronic kidney disease (CKD) has been well established. Therefore, comprehensive management and early intervention are crucial to improving patient outcomes and reducing the strain on medical resources. This narrative review discusses the critical role of renal protection in the context of CKM syndrome, with a focus on the importance of sodium-glucose cotransporter-2 (SGLT-2) inhibitors. These drugs play a significant role in renal protection and in managing a variety of metabolic and cardiovascular disorders or risk factors. Additionally, the review underscores the challenges faced in managing CKM syndrome and suggests potential future directions in China. This reflects a comprehensive approach aimed at enhancing public health strategies in managing the complex interplay among kidney health, cardiovascular function, and metabolic status.
Keywords: sodium-glucose cotransporter-2, cardiovascular-kidney-metabolic syndrome, chronic kidney disease, heart failure, cardiovascular disease, type 2 diabetes mellitus